View Older Stories

Apr 29, 2026 06:54AM Emergent BioSolutions partners with baseball player Davis Schneider for opioid awareness

Apr 28, 2026 08:01AM Emergent BioSolutions partners with Substipharm for JE vaccine manufacturing

Apr 20, 2026 06:40AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Apr 16, 2026 04:06PM Emergent BioSolutions refinances debt, extends maturities to 2031

Apr 9, 2026 04:25PM Emergent BioSolutions partners with British Columbia for naloxone program

Apr 7, 2026 12:42PM Emergent BioSolutions launches NARCAN carrying case and multipacks

Mar 26, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Mar 9, 2026 06:50AM Emergent BioSolutions (EBS) PT Lowered to $12 at H.C. Wainwright

Feb 26, 2026 04:59PM Emergent BioSolutions (EBS) Misses Q4 EPS by 81c

Feb 26, 2026 04:02PM Emergent BioSolutions secures $140 million in Canadian contracts

Jan 12, 2026 07:30AM Emergent BioSolutions pays down $100 million of term loan debt

Jan 8, 2026 04:31PM Emergent BioSolutions gets $21.5 million contract for anthrax vaccine

Jan 8, 2026 08:04AM Emergent BioSolutions provides funding for mpox treatment study in Africa

Nov 12, 2025 04:03PM Emergent BioSolutions board member Sullivan retires after 19 years

Oct 29, 2025 04:41PM Emergent BioSolutions (EBS) Tops Q3 EPS by 101c

Sep 22, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Sep 19, 2025 08:36AM Emergent BioSolutions receives $29 million international order

Sep 16, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Sep 15, 2025 08:36AM Emergent BioSolutions gets $17 million contract for smallpox drug

Sep 11, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Sep 9, 2025 07:31AM Emergent BioSolutions gets $56 million U.S. contract for smallpox vaccine

Sep 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Aug 7, 2025 02:12AM Emergent BioSolutions (EBS) Tops Q2 EPS by 26c

Jul 8, 2025 04:45PM Emergent BioSolutions receives $51.9 million contract for smallpox treatment

Jul 2, 2025 04:05PM Emergent BioSolutions (EBS) Expands NARCANDirect to Offer KLOXXADO Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025 08:06AM Emergent BioSolutions (EBS) Secures $62.4M Contract Modification for BAT

Jun 20, 2025 08:14AM Emergent BioSolutions (EBS) Added to Russell 3000 Index

May 8, 2025 01:45AM Emergent BioSolutions (EBS) Tops Q1 EPS by 22c

Mar 31, 2025 08:03AM Emergent BioSolutions (EBS) Announces Stock Repurchase Program

Mar 19, 2025 04:30PM Emergent BioSolutions (EBS) Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025 08:04AM Emergent BioSolutions (EBS) Announces Approximately $27M in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 10, 2025 09:15AM Emergent BioSolutions (EBS) Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 4, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Mar 3, 2025 04:47PM After-hours movers: Okta, GitLab, New Fortress Energy, Emergent BioSolutions

Mar 3, 2025 04:29PM Emergent BioSolutions (EBS) Tops Q4 EPS by 46c

Jan 21, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)

Jan 14, 2025 07:31AM Emergent BioSolutions (EBS) Gains Exclusive Commercial Rights to KLOXXADO Nasal Spray from Hikma Pharmaceuticals

Jan 13, 2025 09:28AM Emergent BioSolutions (EBS) Receives Contract Option Valued at Approximately $16.7M to Continue Development Collaboration with BARDA on Ebanga

Jan 8, 2025 07:30AM Emergent BioSolutions (EBS) Announces Exercise of $20M Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Dec 30, 2024 06:33AM H.C. Wainwright Starts Emergent BioSolutions (EBS) at Buy

Dec 16, 2024 08:00AM Emergent BioSolutions (EBS) Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS

Nov 7, 2024 08:39AM Emergent BioSolutions (EBS) PT Raised to $12 at Benchmark

Nov 6, 2024 04:57PM Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27

Nov 6, 2024 04:54PM Emergent BioSolutions (EBS) Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Nov 4, 2024 07:30AM Emergent BioSolutions (EBS) Appoints Simon Lowry as Chief Medical Officer, Head of R&D

Oct 2, 2024 07:33AM Emergent BioSolutions (EBS) Announces Closing of $100 Million Asset-Backed Loan Facility

Sep 26, 2024 08:05AM Emergent BioSolutions (EBS) Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA to Support National Preparedness Efforts

Sep 25, 2024 07:32AM Emergent (EBS) Climbs 12% After it Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Sep 25, 2024 07:07AM Emergent BioSolutions (EBS) Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Sep 13, 2024 06:45AM Emergent BioSolutions (EBS) to Settle Securities Class Action Litigation

View Older Stories